Abstract: Service for a machine such as a laboratory instrument can be facilitated by capture of images showing the field of view of a user of the machine, and modification of those images to remove confidential information. Modified images can then be provided to service technicians so that the service technicians can have visual information that would allow them to more effectively communicate and interact with the machines' users.

Abstract: An integrated sample processing system including an analyzer and a mass spectrometer is disclosed. The integrated sample processing system can perform multiple different types of detection, thereby providing improved flexibility and better accuracy in processing samples. The detection systems in the sample processing system may include an optical detection system and a mass spectrometer.

Abstract: One embodiment of the invention is directed to a sample processing system for analyzing a biological sample from a patient. The sample processing system comprises: a plurality of analyzers comprising at least one mass spectrometer, wherein each analyzer in the plurality of analyzers is configured to acquire at least one measurement value corresponding to at least one characteristic of the biological sample; at least one data storage component which stores (i) a list of parameters for the plurality of analyzers, and (ii) at least two condition sets, which contain data associated with completing one or more test orders. The condition sets contain data which differ by at least one variable; and a control system operatively coupled to the plurality of analyzers, and the at least one data storage component.

Abstract: A substance dispense system is provided for a biological sample analysis instrument. The substance dispense system can operate to prepare a fluidic substance, such as a sample, using a dispense tip in different operational modes based on the volume of the fluid substance to be prepared. The substance dispense system thereby improves accuracy and/or precision in pipetting with the dispense tip.

Abstract: Automatic substance preparation and evaluation systems and methods are provided for preparing and evaluating a fluidic substance, such as e.g. a sample with bodily fluid, in a container and/or in a dispense tip. The systems and methods can detect volumes, evaluate integrities, and check particle concentrations in the container and/or the dispense tip.

Abstract: The invention provides a microRNA inhibitor that has two or more sequences complementary to the sequence of microRNA to be the target of inhibition, which two or more complementary sequences are linked via one or more linker residues.

Abstract: An automatic analyzer capable of avoiding carry-over between samples, and a sample dispensing method, are provided. To that end, an automatic analyzer (1) for performing analysis of both assay menu with a high carry-over avoiding level and assay menu with a low carry-over avoiding level, includes: a first sample dispensing apparatus (6) loaded with a disposable tip (60a) for sample dispensing for assay menu with a high carry-over avoiding level, and for subdividing and dispensing a sample for assay menu with a low carry-over avoiding level; an aliquot container (9) for subdividing and containing a sample for assay menu with a low carry-over avoiding level, subdivided and dispensed by the first sample dispensing apparatus (6); and a second sample dispensing apparatus (5) loaded with a reusable probe (50), for sample dispensing for assay menu with a low carry-over avoiding level.

Abstract: The invention provides a microRNA inhibitor that has two or more sequences complementary to the sequence of microRNA to be the target of inhibition, which two or more complementary sequences are linked via one or more linker residues.

Abstract: The invention provides a microRNA inhibitor that has two or more sequences complementary to the sequence of microRNA to be the target of inhibition, which two or more complementary sequences are linked via one or more linker residues.

Abstract: The present invention provides a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject, and an evaluation method using the same. A cancer marker containing at least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as a marker for cancers excluding breast cancer. A method for evaluating the possibility of cancers excluding breast cancer includes the step of detecting the expression level of a cancer marker in a biological sample collected from a subject. In this method, the cancer marker contains at least one miRNA selected from hsa-miR-92 and hsa-miR-494.

Abstract: An automatic analyzer capable of avoiding carry-over between samples, and a sample dispensing method, are provided. To that end, an automatic analyzer (1) for performing analysis of both assay menu with a high carry-over avoiding level and assay menu with a low carry-over avoiding level, includes: a first sample dispensing apparatus (6) loaded with a disposable tip (60a) for sample dispensing for assay menu with a high carry-over avoiding level, and for subdividing and dispensing a sample for assay menu with a low carry-over avoiding level; an aliquot container (9) for subdividing and containing a sample for assay menu with a low carry-over avoiding level, subdivided and dispensed by the first sample dispensing apparatus (6); and a second sample dispensing apparatus (5) loaded with a reusable probe (50), for sample dispensing for assay menu with a low carry-over avoiding level.

Abstract: Provided is a novel molecule that inhibits the expression of the periostin gene. Also provided are methods of inhibiting the expression of the periostin gene or treating an eye disease using the same.

Abstract: The invention provides a microRNA inhibitor that has two or more sequences complementary to the sequence of microRNA to be the target of inhibition, which two or more complementary sequences are linked via one or more linker residues.

Abstract: The present invention provides a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject, and an evaluation method using the same. A cancer marker containing at least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as a marker for cancers excluding breast cancer. A method for evaluating the possibility of cancers excluding breast cancer includes the step of detecting the expression level of a cancer marker in a biological sample collected from a subject. In this method, the cancer marker contains at least one miRNA selected from hsa-miR-92 and hsa-miR-494.

Abstract: The present invention provides a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject, and an evaluation method using the same. A cancer marker containing at least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as a marker for cancers excluding breast cancer. A method for evaluating the possibility of cancers excluding breast cancer includes the step of detecting the expression level of a cancer marker in a biological sample collected from a subject. In this method, the cancer marker contains at least one miRNA selected from hsa-miR-92 and hsa-miR-494.

Abstract: The present invention provides a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject, and an evaluation method using the same. A cancer marker containing at least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as a marker for cancers excluding breast cancer. A method for evaluating the possibility of cancers excluding breast cancer includes the step of detecting the expression level of a cancer marker in a biological sample collected from a subject. In this method, the cancer marker contains at least one miRNA selected from hsa-miR-92 and hsa-miR-494.

Abstract: An embodiment of the present invention provides a marker, a test method, and a test kit which can detect the onset of breast cancer that cannot be detected by palpation or mammography examination or breast cancer in an early stage (clinical stage 0), which are simple, and which have high reliability. A marker associated with breast cancer of an embodiment of the present invention is characterized by being a micro-RNA that is found in serum or plasma. More specifically, the marker contains at least a micro-RNA that is present in the serum or the plasma at a significantly reduced level after the onset of breast cancer, or during or after an early stage (during or after clinical stage 0) of breast cancer compared with that before the onset of breast cancer or before the early stage (before clinical stage 0) of breast cancer.